‘Disclose the pricing rationale used for COVID-19 drugs'

By Kang, Hye-Kyung | translator Alice Kang

24.10.02 05:10:02

가나다라 0

"MOHW’s decision to set the price of Paxlovid-Veklury Inj at KRW 0.94 million-KRW 3.12 million is not acceptable”

"Healthcare finances is not MOHW’s private finances… stop filling the bellies of pharmaceutical companies”

The Korean Pharmacists for Democratic Society (CEO Kyungrim Jeon, KPDS) has called for the disclosure of the cost-effectiveness evaluation results of the COVID-19 treatments Paxlovid and Veklury Inj.

“The Ministry of Health and Welfare is engaging in the atrocity of setting excessive drug prices for COVID-19 treatments,” said the KPDS on the 30th, adding, “Much question remains on the clinical utility of current COVID-19 treatments among vaccinated elderly patients, and the KPDS criticizes the Ministry of Health and Welfare for setting an unreasonable price and the arbitrary co-payment rates, which only filling the bellies of pharmaceutical companies.”

“In addition to filling the me

Kang, Hye-Kyung(khk@dailypharm.com )

If you want to see the full article, please JOIN US (click)